瑞普生物
(300119)
| 流通市值：55.08亿 | | | 总市值：75.62亿 |
| 流通股本：3.39亿 | | | 总股本：4.65亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,670,506,885.08 | 1,720,460,367.77 | 826,126,074.24 | 3,398,458,452.83 |
| 营业收入 | 2,670,506,885.08 | 1,720,460,367.77 | 826,126,074.24 | 3,398,458,452.83 |
| 二、营业总成本 | 2,328,498,364.54 | 1,487,878,552.08 | 704,661,498.03 | 3,020,087,411.56 |
| 营业成本 | 1,608,878,312.01 | 1,036,930,674.4 | 497,907,185.78 | 1,995,662,711.33 |
| 税金及附加 | 26,529,145.97 | 18,070,830.36 | 8,142,841.64 | 28,019,597.7 |
| 销售费用 | 329,657,280.84 | 207,372,707.67 | 96,171,383.81 | 503,814,789.02 |
| 管理费用 | 162,278,017.93 | 100,701,092.18 | 48,489,451.57 | 204,913,175.43 |
| 研发费用 | 173,134,476.91 | 107,352,173.23 | 45,325,880.26 | 253,019,299.62 |
| 财务费用 | 28,021,130.88 | 17,451,074.24 | 8,624,754.97 | 34,657,838.46 |
| 其中:利息费用 | 25,917,749.12 | 16,058,154.9 | 8,160,574.95 | 35,158,001.14 |
| 其中:利息收入 | 1,720,322.05 | 1,130,326.46 | 588,793.52 | 2,489,936.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 18,853,033.18 | 10,086,942.92 | 4,394,555.81 | 75,831,147.54 |
| 加:投资收益 | 7,551,831.42 | 6,666,382.23 | 9,058,766.74 | 34,221,849.5 |
| 资产处置收益 | 64,979.27 | 2,822.84 | - | 3,819,392.15 |
| 资产减值损失(新) | 875,861.84 | 21,895.03 | 21,895.03 | -6,845,074.75 |
| 信用减值损失(新) | -23,371,659.66 | -17,781,269.74 | -10,386,586.72 | -34,589,852.5 |
| 其他收益 | 30,047,968.3 | 8,480,297.25 | 4,051,948.12 | 28,776,416.74 |
| 四、营业利润 | 376,030,534.89 | 240,058,886.22 | 128,605,155.19 | 479,584,919.95 |
| 加:营业外收入 | 1,720,228.87 | 1,515,901.04 | 191,121.65 | 2,294,049.6 |
| 减:营业外支出 | 3,087,972.76 | 589,296.03 | 332,832.89 | 11,188,338.23 |
| 五、利润总额 | 374,662,791 | 240,985,491.23 | 128,463,443.95 | 470,690,631.32 |
| 减:所得税费用 | 30,583,848.46 | 19,070,251.43 | 11,054,602.15 | 36,221,382.29 |
| 六、净利润 | 344,078,942.54 | 221,915,239.8 | 117,408,841.8 | 434,469,249.03 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 344,078,942.54 | 221,915,239.8 | 117,408,841.8 | 434,469,249.03 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 298,844,849.19 | 204,105,426.38 | 107,778,219.26 | 400,513,483.64 |
| 少数股东损益 | 45,234,093.35 | 17,809,813.42 | 9,630,622.54 | 33,955,765.39 |
| 扣除非经常损益后的净利润 | 259,810,962.52 | 184,339,567.88 | 95,468,233.84 | 304,522,472.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.66 | 0.45 | 0.24 | 0.88 |
| (二)稀释每股收益 | 0.66 | 0.45 | 0.24 | 0.88 |
| 八、其他综合收益 | - | - | - | 45,528.73 |
| 归属于母公司股东的其他综合收益 | - | - | - | 45,528.73 |
| 九、综合收益总额 | 344,078,942.54 | 221,915,239.8 | 117,408,841.8 | 434,514,777.76 |
| 归属于母公司股东的综合收益总额 | 298,844,849.19 | 204,105,426.38 | 107,778,219.26 | 400,559,012.37 |
| 归属于少数股东的综合收益总额 | 45,234,093.35 | 17,809,813.42 | 9,630,622.54 | 33,955,765.39 |
| 公告日期 | 2026-10-28 | 2026-08-26 | 2026-04-28 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |